Accessibility Menu
Precipio logo

Precipio(NASDAQ) PRPO

Current Price$23.75
Market Cap$42.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-99%
5 Year-61%
1 Year+67%
1 Month+3%
Precipio last closing stock price
MetricPriceDate
Last closeUSD 23.682026-07-24
Precipio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.9%USD 24.642026-07-17
1 month+3.13%USD 22.962026-06-24
3 month-15.41%USD 28.002026-04-24
Year to date+3.05%USD 22.982025-12-31
1 year+66.64%USD 14.212025-07-24
3 year+263.19%USD 6.522023-07-25
5 year-60.79%USD 60.402021-07-23
Since inception-99.12%USD 2,700.002017-06-30

Precipio Financials at a Glance

Market Cap

$42.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$26.09M

Net Income (TTM)

-$922.00K

EPS (TTM)

-$0.52

P/E Ratio

-45.89

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$23.75

Volume

1,388

Open

$23.38

Previous Close

$23.75

Daily Range

$22.55 - $23.75

52-Week Range

$13.80 - $33.63

Estimated Earnings Date

Jul 30, 2026

PRPO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Precipio

Precipio helps doctors diagnose blood cancers more accurately and quickly. Its tests and tools support healthcare providers in finding the right diagnosis. The company’s products aim to reduce misdiagnosis and improve patient care.

Lab Coats & Test Tubes: What Precipio Sells

  • Diagnostic Services (89% of Q2 2025 revenue): Blood cancer testing for oncologists and healthcare providers across the US.
  • Reagents and Consumables: Chemical sets and supplies for use with Precipio’s diagnostic platforms, mainly for labs and bio-pharma clients.
  • COVID-19 Antibody Tests: Tests to detect past COVID-19 infection, sold to healthcare providers.
  • Collaborative Services: Partnerships with academic centers for cancer research and diagnostic development.

Growth Spurts & Strategic Moves

  • Expanded distribution through partnerships with ThermoFisher, McKesson, Medline, and Cardinal Health (2023-2025).
  • Launched HemeScreen Reagent Rental program and ICE-COLD PCR kits for bio-pharma customers (2024-2025).
  • Invested $0.2 million in new lab equipment and facilities in the first half of 2025.
  • Increased case processing volume by 19% year-over-year in Q2 2025.

Why Precipio Isn’t Just Another Lab

Precipio uses its own clinical lab to test and refine new products, speeding up development and reducing costs. The company’s direct use of its technologies allows for real-world optimization before wider release. Distribution deals with major healthcare suppliers help broaden its reach in the diagnostics market.

Five Things You Need to Know

  • Net sales were $5.65 million in Q2 2025, up 27% from Q2 2024.
  • Gross margin rose to 43% in Q2 2025, up from 39% a year earlier.
  • Q2 2025 net income was $74,000, compared to a $1.22 million loss in Q2 2024.
  • Working capital deficit was $0.3 million as of June 30, 2025.
  • Customer C made up 27% of Q2 2025 net sales and 25% of receivables.

Bottom Line

Precipio has grown by expanding its product range and distribution partnerships. The company’s focus on innovation and operational efficiency supports its position in the diagnostics market.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

61

CEO

Ilan Danieli, MBA

Website

www.precipiodx.com

Headquarters

New Haven, CT 06511, US

PRPO Financials

Key Financial Metrics (TTM)

Gross Margin

43.27%

Operating Margin

-6.79%

Net Income Margin

-3.53%

Return on Equity

-6.73%

Return on Capital

-6.60%

Return on Assets

-4.43%

Earnings Yield

-2.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$42.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.79M

Volume

1.39K

Avg. Volume

53.87K

Financials (TTM)

Gross Profit

$11.29M

Operating Income

-$1.77M

EBITDA

$860.00K

Operating Cash Flow

$793.00K

Capital Expenditure

-$238.00K

Free Cash Flow

$555.00K

Cash & ST Invst.

$2.60M

Total Debt

$3.49M

Precipio Performance Analysis

Precipio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 9,412,0006.4%
20232023-12-31USD 15,197,00061.5%
20242024-12-31USD 18,532,00021.9%
20252025-12-31USD 24,049,00029.8%
Precipio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3032.8%
Q32025-09-309.0%
Q42025-12-3129.4%
Q12026-03-31-21.0%
Precipio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.7332.7%
20232023-12-31USD -4.51-58.0%
20242024-12-31USD -2.93-35.1%
20252025-12-31USD -0.23-92.3%
Precipio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30107.8%
Q32025-09-30-208.2%
Q42025-12-31760.0%
Q12026-03-31-345.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$6.30M

+48.0%

Gross Profit

$2.73M

+27.3%

Gross Margin

43.24%

N/A

Market Cap

$42.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$693.85K

N/A

Employees

61

N/A

Net Income

-$1.44M

-63.2%

EBITDA

-$971.00K

-119.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.60M

+156.0%

Total Debt

$3.49M

+56.4%

Accounts Receivable

$1.99M

+103.7%

Inventory

$870.00K

+5.5%

Long Term Debt

$2.83M

+60.9%

Short Term Debt

$666.00K

+39.6%

Return on Assets

-4.43%

N/A

Return on Invested Capital

-10.42%

N/A

Free Cash Flow

$14.00K

+107.7%

Operating Cash Flow

$64.00K

+245.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
STRRStar Equity Holdings, Inc.
$10.85+2.84%
POCIPrecision Optics Corporation, Inc.
$4.30+0.00%
PLURPluri Inc.
$1.78-0.84%
LDDDLongduoduo Company Limited
$0.51+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About PRPO

What is the current price of Precipio?

Precipio is trading at $23.75 per share.

What is the 52-week range for Precipio?

Over the past 52 weeks, Precipio has traded between $13.80 and $33.63.

How much debt does Precipio have?

As of the most recent reporting period, Precipio reported total debt of $3.49M.

How much cash does Precipio have on hand?

Precipio reported $2.60M in cash and cash equivalents in its most recent financial results.

What is Precipio’s dividend yield?

Precipio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services